Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry

Canakinumab was effective as a first-line biologic therapy for Still's disease, regardless of whether it presents as systemic or chronic-articular. Early initiation of IL-1 inhibition may further enhance results. #Still'sdisease #canakinumab https://t.co